We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-20.92%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$220M
AUM Growth
-$80.2M
Cap. Flow
-$4.32M
Cap. Flow %
-1.97%
Top 10 Hldgs %
80.97%
Holding
32
New
7
Increased
6
Reduced
4
Closed
7
Avg Time Held Equity + Options
0.4 years
Top 10 Avg Time Held Equity + Options
0.5 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.5 years
Top 20 Avg Time Held Equity only
0.5 years

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$19.7M
2
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$8.86M
3
ASMB icon
Assembly Biosciences
ASMB
+$4.59M
4
CASC
Cascadian Therapeutics, Inc.
CASC
+$3.22M
5
OREX
Orexigen Therapeutics, Inc.
OREX
+$3.21M

Top Sells

Rank Stock Value
1
ATRA icon
Atara Biotherapeutics
ATRA
+$12.7M
2
EPZM
Epizyme, Inc
EPZM
+$3.9M
3
ARRY icon
Array Biopharma Inc
ARRY
+$2.88M
4
BITI icon
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
+$2M
5
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$1.71M

Sector Composition

Rank Sector Weight
1 Healthcare 88.28%
2 Miscellaneous 11.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TPST icon
26
CALL
Tempest Therapeutics
TPST
$10.7M
– –
-1
Closed -$6.65M –
XENE icon
27
Xenon Pharmaceuticals
XENE
$3.32B
– –
-73,000
Closed -$842K –
EPZM
28
CALL
DELISTED
Epizyme, Inc
EPZM
– –
-150
Closed -$360K –
ARRY icon
29
CALL
DELISTED
Array Biopharma Inc
ARRY
– –
-11,000
Closed -$7.93M –
ARRY icon
30
DELISTED
Array Biopharma Inc
ARRY
– –
-400,000
Closed -$2.88M –
BITI icon
31
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
– –
-100,000
Closed -$2M –
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2015 Portfolio in Review

As of Q3 2015, EcoR1 Capital held 32 positions worth $220M, down 27% from $300M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

EcoR1 Capital's Q3 2015 filing shows 7 new, 6 increased, 4 reduced and 7 closed positions. Its largest new stake was Nabriva Therapeutics plc Ordinary Shares Ireland: 3,342 shares worth $7.94M. The largest sale was Atara Biotherapeutics, an estimated $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q3 2015 buy was Nabriva Therapeutics plc Ordinary Shares Ireland: 3,342 shares worth $7.94M.
  • EcoR1 Capital added most to Travere Therapeutics in Q3 2015, an estimated $19.7M increase.
  • EcoR1 Capital's biggest Q3 2015 reduction was Atara Biotherapeutics, cutting an estimated $12.7M.
  • EcoR1 Capital fully exited Array Biopharma Inc in Q3 2015, selling an estimated $2.88M.
  • EcoR1 Capital's ten largest holdings make up 81% of its $220M portfolio in Q3 2015.
  • EcoR1 Capital opened 7 new positions and closed 7 in Q3 2015.
  • EcoR1 Capital's portfolio value fell 27% quarter-over-quarter to $220M.

Based on EcoR1 Capital's 13F filing for Q3 2015, filed 16 Nov 2015.